The Biospecimen Access and Analysis Core (formerly the Tissue and Pathology Core) has the primary charges of providing an efficient, cost-effective, and user-friendly infrastructure for 1) making available the necessary biospecimens (cells, fluids, tissues) required for execution of the five SPORE Projects, 2) facilitation and maintenance of a relevant database of clinicopathological parameters, and 3) provision of specialized pathology analysis, both technical and professional, integral to accrual of translationally-relevant data. Implicit to these objectives is the ongoing development and refinement of existing resources to better meet the anticipated future needs of the SPORE program as a whole. The organizational framework of this Core involves a centralized facility (located at Eugene Braunwald Research Center) for coordination of all Core activities that capitalize on and integrate the collective and complementary expertise and resources of four Harvard Medical Institutions (Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Dana Farber Cancer Institute, and Massachusetts General Hospital). Thus, the Core is designed to function as a coordinator and facilitator of tissue archiving, access, and ongoing accrual, as well as of specialized analysis of biospecimens. Importantly, the Core is specifically engineered to foster collaborative interactions, promote development of relevant new technologies, and provide cost-effective tools for coordination and utilization of the substantial pathology resources of the Harvard Medical Institutions. The Core services are available to all SPORE investigators, Dana Farber/Harvard Cancer Center members, and collaborating investigators based on prioritization criteria administered by the Biospecimen Access and Analysis Executive Committee.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA093683-10
Application #
8380231
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
2014-01-31
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
10
Fiscal Year
2012
Total Cost
$195,736
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Sung, Hyeran; Kanchi, Krishna L; Wang, Xue et al. (2016) Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation. Oncotarget 7:23885-96
Jain, Salvia; Stroopinsky, Dina; Yin, Li et al. (2015) Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. Blood 126:354-62
Lee, Jonathan J; Granter, Scott R; Laga, Alvaro C et al. (2015) 5-Hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in sentinel lymph node biopsies. Mod Pathol 28:218-29
Bhela, Siddheshvar; Kempsell, Christine; Manohar, Monali et al. (2015) Nonapoptotic and extracellular activity of granzyme B mediates resistance to regulatory T cell (Treg) suppression by HLA-DR-CD25hiCD127lo Tregs in multiple sclerosis and in response to IL-6. J Immunol 194:2180-9
Lee, Jonathan J; Cook, Martin; Mihm, Martin C et al. (2015) Loss of the epigenetic mark, 5-Hydroxymethylcytosine, correlates with small cell/nevoid subpopulations and assists in microstaging of human melanoma. Oncotarget 6:37995-8004
Watanabe, Rei; Gehad, Ahmed; Yang, Chao et al. (2015) Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells. Sci Transl Med 7:279ra39
Kirsch, Ilan R; Watanabe, Rei; O'Malley, John T et al. (2015) TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Sci Transl Med 7:308ra158
Litvinov, Ivan V; Netchiporouk, Elena; Cordeiro, Brendan et al. (2015) The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL). Clin Cancer Res 21:2820-9
Yazawa, Erika M; Geddes-Sweeney, Jenna E; Cedeno-Laurent, Filiberto et al. (2015) Melanoma Cell Galectin-1 Ligands Functionally Correlate with Malignant Potential. J Invest Dermatol 135:1849-62
Lezcano, Cecilia; Lee, Chung-Wei; Larson, Allison R et al. (2014) Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. Mod Pathol 27:1193-202

Showing the most recent 10 out of 129 publications